Literature DB >> 20856769

The 2007 national practice benchmark: results of a national survey of oncology practices.

Thomas R Barr, Elaine L Towle, William M Jordan.   

Abstract

Long-term trends in the cost of pharmaceutical goods purchased by community oncology practices seem to have dramatically changed in 2007, potentially ending an era of practice growth built on the economic engine of in-office chemotherapy provision.

Year:  2008        PMID： 20856769      PMCID： PMC2793960          DOI： 10.1200/JOP.0843501

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


  2 in total

1.  Key practice indicators in office-based oncology practices: 2007 report on 2006 data.

Authors:  John Akscin; Thomas R Barr; Elaine L Towle
Journal:  J Oncol Pract       Date:  2007-07       Impact factor: 3.840

2.  Disruptive innovation: can health care learn from other industries? A conversation with Clayton M. Christensen. Interview by Mark D. Smith.

Authors:  Clayton M Christensen
Journal:  Health Aff (Millwood)       Date:  2007-03-13       Impact factor: 6.301
  2 in total
  5 in total

1.  Oncology Practice Trends From the National Practice Benchmark, 2005 through 2010.

Authors:  Thomas R Barr; Elaine L Towle
Journal:  J Oncol Pract       Date:  2011-09       Impact factor: 3.840

2.  2009 national practice benchmark: report on 2008 data.

Authors:  Elaine L Towle; Thomas R Barr
Journal:  J Oncol Pract       Date:  2009-09       Impact factor: 3.840

3.  Access, quality, and cost.

Authors:  John V Cox
Journal:  J Oncol Pract       Date:  2009-09       Impact factor: 3.840

4.  National oncology practice benchmark: an annual assessment of financial and operational parameters-2010 report on 2009 data.

Authors:  Thomas R Barr; Elaine L Towle
Journal:  J Oncol Pract       Date:  2011-03       Impact factor: 3.840

5.  Oncology practice trends from the national practice benchmark.

Authors:  Thomas R Barr; Elaine L Towle
Journal:  J Oncol Pract       Date:  2012-09       Impact factor: 3.840
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.